Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine.
2-Chlorodeoxyadenosine (CdA) is active in chronic lymphocytic leukemia, hairy-cell leukemia, and low-grade lymphomas. In part, this spectrum of activity may be attributable to the selective toxicity of CdA to nondividing lymphocytes and monocytes. However, CdA is unstable at acidic pH and is degraded by bacterial nucleoside phosphorylases. The present experiments demonstrate that the 2'-arabino-fluoro derivative of CdA, designated CAFdA, is also directly toxic to quiescent lymphocytes and macrophages. Unlike CdA, CAFdA was stable at pH 2 and resisted degradation by Escherichia coli nucleoside phosphorylase. Cell killing was preceded by the formation of DNA strand breaks and could be prevented by supplementation of the medium with deoxycytidine. The initial DNA damage initiated the pattern of oligonucleosomal DNA fragmentation characteristic of apoptosis. Mutant lymphoblasts, deficient in deoxycytidine kinase, with elevated cytoplasmic 5'-nucleotidase, or with expanded deoxynucleotide pools secondary to increased ribonucleotide reductase activity, were cross-resistant to both CAFdA and CdA toxicity. One-week oral treatment with CAFdA (1 mg/ml in drinking water) achieved an average plasma concentration of 0.56 microM and eliminated 90% of chronic lymphocytic leukemia cells transplanted into severe combined immunodeficiency (scid) mice. Under the same conditions, CdA was much less active. Collectively, these results suggest that CAFdA could be effective as an oral agent in indolent lymphoproliferative diseases and in autoimmune diseases where lymphocyte and monocyte depletion is desirable.
Carson
D A
DA
Department of Medicine, University of California, San Diego, La Jolla 92093-0663.
Wasson
D B
DB
Esparza
L M
LM
Carrera
C J
CJ
Kipps
T J
TJ
Cottam
H B
HB
D015762:2-Chloroadenosine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity; D000227:Adenine Nucleotides; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity*; D001087:Arabinonucleosides / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity*; D016923:Cell Death / Q000187:drug effects*; D017338:Cladribine; D000077866:Clofarabine; D004247:DNA / Q000187:drug effects; D004249:DNA Damage; D003839:Deoxyadenosines / Q000737:chemistry / Q000493:pharmacokinetics / Q000633:toxicity*; D007943:Leukemia, Hairy Cell / Q000188:drug therapy; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008214:Lymphocytes / Q000187:drug effects*; D051379:Mice; D016513:Mice, SCID; D009000:Monocytes / Q000187:drug effects*
D000227:Adenine Nucleotides; D000964:Antimetabolites, Antineoplastic; D001087:Arabinonucleosides; D003839:Deoxyadenosines; D015762:2-Chloroadenosine; D017338:Cladribine; D000077866:Clofarabine; D004247:DNA